Effective Chemoimmunotherapy by Co-delivery of Doxorubicin and Immune Adjuvants in Biodegradable Nanoparticles

Overview

Journal Theranostics

Date 2019 Oct 8

PMID 31588231

Citations 22

Authors

Candido G Da Silva

Marcel G M Camps

Tracy M W Y Li

Luana Zerrillo

Clemens W Lowik

Ferry Ossendorp

Luis J Cruz

Affiliations

Soon will be listed here.

Abstract

Chemoimmunotherapy is an emerging combinatorial modality for the treatment of cancers resistant to common first-line therapies, such as chemotherapy and checkpoint blockade immunotherapy. We used biodegradable nanoparticles as delivery vehicles for local, slow and sustained release of doxorubicin, two immune adjuvants and one chemokine for the treatment of resistant solid tumors. Bio-compatible poly(lactic-co-glycolic acid)-PEG nanoparticles were synthesized in an oil/water emulsion, using a solvent evaporation-extraction method. The nanoparticles were loaded with a NIR-dye for theranostic purposes, doxorubicin cytostatic agent, poly (I:C) and R848 immune adjuvants and CCL20 chemokine. After physicochemical and characterization the nanoparticles therapeutic efficacy were carried-out on established, highly aggressive and treatment resistant TC-1 lung carcinoma and MC-38 colon adenocarcinoma models . The yielded nanoparticles average size was 180 nm and -14 mV surface charge. The combined treatment with all compounds was significantly superior than separate compounds and the compounds nanoparticle encapsulation was required for effective tumor control . The mechanistic studies confirmed strong induction of circulating cancer specific T cells upon combined treatment in blood. Analysis of the tumor microenvironment revealed a significant increase of infiltrating leukocytes upon treatment. The multi-drug loaded nanoparticles mediated delivery of chemoimmunotherapy exhibited excellent therapeutic efficacy gain on two treatment resistant cancer models and is a potent candidate strategy to improve cancer therapy of solid tumors resistant to first-line therapies.

Citing Articles

CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.

Kwantwi L, Boafo J, Egleh B, Li M Clin Transl Oncol. 2025; .

PMID: 39985603 DOI: 10.1007/s12094-025-03874-5.

Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment.

Lang X, Wang X, Han M, Guo Y Int J Nanomedicine. 2024; 19:4533-4568.

PMID: 38799699 PMC: 11127654. DOI: 10.2147/IJN.S455213.

Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.

Wang S, Li J, Hong S, Wang N, Xu S, Yang B J Exp Clin Cancer Res. 2024; 43(1):121.

PMID: 38654356 PMC: 11036662. DOI: 10.1186/s13046-024-03050-7.

Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer.

Yuan H, Gui H, Chen S, Zhu L, Wang C, Jing Q Int J Nanomedicine. 2024; 19:3589-3605.

PMID: 38645464 PMC: 11032718. DOI: 10.2147/IJN.S450205.

Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy.

Sharma P, Otto M Bioact Mater. 2023; 31:440-462.

PMID: 37701452 PMC: 10494322. DOI: 10.1016/j.bioactmat.2023.08.022.

References

Levine A, Levy H . Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep. 1978; 62(11):1907-12. View

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

Heo M, Kim S, Yun W, Lim Y . Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J Nanomedicine. 2015; 10:5981-92. PMC: 4590313. DOI: 10.2147/IJN.S90104. View

Shen F, Chu S, Bence A, Bailey B, Xue X, Erickson P . Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2007; 324(1):95-102. DOI: 10.1124/jpet.107.127704. View

Jackaman C, Lew A, Zhan Y, Allan J, Koloska B, Graham P . Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008; 20(11):1467-79. DOI: 10.1093/intimm/dxn104. View

LaVan D, McGuire T, Langer R . Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003; 21(10):1184-91. DOI: 10.1038/nbt876. View

Amos S, Pegram H, Westwood J, John L, Devaud C, Clarke C . Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011; 60(5):671-83. PMC: 3499620. DOI: 10.1007/s00262-011-0984-8. View

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

10.

Zom G, Khan S, Britten C, Sommandas V, Camps M, Loof N . Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res. 2014; 2(8):756-64. DOI: 10.1158/2326-6066.CIR-13-0223. View

11.

Schutyser E, Struyf S, Van Damme J . The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003; 14(5):409-26. DOI: 10.1016/s1359-6101(03)00049-2. View

12.

Tel J, Lambeck A, Cruz L, Tacken P, de Vries I, Figdor C . Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol. 2010; 184(8):4276-83. DOI: 10.4049/jimmunol.0903286. View

13.

Suet Ting Tan R, Lin B, Liu Q, Tucker-Kellogg L, Ho B, Leung B . The synergy in cytokine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages. Immunol Cell Biol. 2013; 91(5):377-87. DOI: 10.1038/icb.2013.13. View

14.

Cruz L, Stammes M, Que I, van Beek E, Knol-Blankevoort V, Snoeks T . Effect of PLGA NP size on efficiency to target traumatic brain injury. J Control Release. 2015; 223:31-41. DOI: 10.1016/j.jconrel.2015.12.029. View

15.

Mundargi R, Babu V, Rangaswamy V, Patel P, Aminabhavi T . Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2007; 125(3):193-209. DOI: 10.1016/j.jconrel.2007.09.013. View

16.

Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B . Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301. DOI: 10.1038/nrc.2017.17. View

17.

Moghimi S, Hunter A, Andresen T . Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2011; 52:481-503. DOI: 10.1146/annurev-pharmtox-010611-134623. View

18.

Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler H, Schlosser H, Schlaak M . Cytokine release syndrome. J Immunother Cancer. 2018; 6(1):56. PMC: 6003181. DOI: 10.1186/s40425-018-0343-9. View

19.

Talmadge J, Adams J, Phillips H, Collins M, Lenz B, Schneider M . Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose. Cancer Res. 1985; 45(3):1058-65. View

20.

Ye J, Ma C, Hsueh E, Dou J, Mo W, Liu S . TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med. 2014; 6(10):1294-311. PMC: 4287933. DOI: 10.15252/emmm.201403918. View